Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delavirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | MAOA | P21397 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | MDH1 | P40925 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.98 |
| ▸ | SYK | P43405 | 14/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delavirdine SCHEMBL3221265 | 1.00 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29585604 | 1.00 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30703160 | 0.99 | ADRA2A (0.97) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29602259 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29714124 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30803764 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL34420 | 0.99 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL28170537 | 0.98 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29746247 | 0.98 | ADRA2A (0.97) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL6390522 | 0.91 | ADRA2A (0.82) | ADRA2AADORA3CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10010 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| EP-4547335-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4547711-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| CN-115590965-B | APTC conjugates for the treatment and/or prophylaxis of HIV-related diseases and uses thereof | 前沿生物药业(南京)股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-115919823-B | Application of benserazide hydrochloride in preparing medicament for treating diseases caused by respiratory syncytial virus | 浙江艾特为生物科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117677631-A | Novel compositions and methods for treating coronavirus infections | 昆士兰医学研究所理事会 | 2024-03-08 | — | — | CN | claimed |
| EP-4326757-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS | The Council of the Queensland Institute of Medical Research (AU) | 2024-02-28 | — | — | EP | claimed |
| EP-0999826-A1 | SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-05-17 | — | — | EP | claimed |
| WO-2000000478-A1 | SUBSTITUTED QUINOXALIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2000-01-06 | — | — | WO | claimed |
| WO-1999063970-A1 | DELAVIRDINE TABLET FORMULATION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-16 | — | — | WO | claimed |
| EP-0929533-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | Du Pont Pharmaceuticals Company (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1999011635-A1 | 5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-11 | — | — | WO | claimed |
| US-5874430-A | COMPOUNDS AS PROTEASE, REVERSE TRANSCRIPTASE INHIBITORS FOR DIAGNOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | claimed |
| WO-1999006024-A1 | SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| EP-0877613-A2 | USE OF A COMBINATION OF DELAVIRDINE AND ONE OR MORE PROTEASE INHIBITORS IN HIV-1 INFECTED PATIENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-11-18 | — | — | EP | claimed |
| WO-1998014436-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-09 | — | — | WO | claimed |
| WO-1997026880-A2 | USE OF A COMBINATION OF DELAVIRDINE AND ONE OR MORE PROTEASE INHIBITORS IN HIV-1 INFECTED PATIENTS | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-31 | — | — | WO | claimed |